Integrative Mendelian randomization and multi-omics analysis identifies anti-allergic drug targets associated with cardiovascular disease risk

by Biotech Newsroom


A comprehensive MR analysis was performed on 139 eQTLs linked to anti-allergic drugs within discovery cohorts of 122,733 CAD patients, 68,157 HF patients, 395,795 MI patients, and 60,620 AF patients. Subsequently, these eQTLs were validated in replication cohorts including 42,096 CAD patients, 47,309 HF patients, 28,546 MI patients, and 55,853 AF patients. The analysis identified 51 eQTLs associated with anti-allergic drugs that are linked to CVDs. Specifically, 8 eQTLs were related to CAD, 34 to HF, 9 to AF, and 13 to MI. Enrichment…



Source link

You may also like

Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:

Free Magazines

Recent Articles

BioTech Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC